Abstract-Several studies implicate elevated matrix metalloproteinase activity as a cause of cardiac fibrosis. However, it is unknown whether other proteases can also initiate cardiac fibrosis. Because absence of urokinase plasminogen activator (uPA) prevents development of cardiac fibrosis after experimental myocardial infarction in mice, we hypothesized that elevated activity of uPA or deficiency of the uPA inhibitor plasminogen activator inhibitor-1 (PAI-1) might cause cardiac fibrosis. We used mice with scavenger-receptor (SR)-directed, macrophage-targeted uPA overexpression (SR-uPA ϩ/0 mice) and PAI-1 null mice to test these hypotheses. Our studies revealed that SR-uPA
mice developed cardiac fibrosis beginning between 5 and 10 weeks of age. Fibrosis was preceded by cardiac macrophage accumulation, implicating uPA-secreting macrophages as important contributors to development of fibrosis. A key role for uPA-secreting macrophages in development of cardiac fibrosis was supported by experiments in which recipients of bone marrow transplants from SR-uPA ϩ/0 donors but not nontransgenic donors developed cardiac macrophage accumulation and fibrosis. SR-uPA ϩ/0 mice and recipients of SR-uPA ϩ/0 bone marrow had neither macrophage accumulation nor fibrosis in other major organs despite the presence of higher levels of uPA in these organs than in hearts. PAI-1 null mice but not congenic, age-matched controls also developed macrophage accumulation and fibrosis in hearts but not in other organs. We conclude: (1) either elevated macrophage uPA expression or PAI-1 deficiency is sufficient to cause cardiac macrophage accumulation and fibrosis; (2) macrophages are important contributors to the development of cardiac fibrosis; and (3) the heart is particularly sensitive to the effects of excess uPA activity. Key Words: cardiac disease Ⅲ collagen Ⅲ inflammation Ⅲ metalloproteinases C ardiac fibrosis, the abnormal accumulation of extracellular matrix (ECM) in the heart, is a common feature of ischemic and nonischemic end-stage heart disease. 1, 2 Fibrotic hearts have impaired systolic as well as diastolic function and are prone to ventricular arrhythmias. [3] [4] [5] Cardiac fibrosis is found in hearts in which myocytes have been lost because of toxic or ischemic injury. In this setting, the fibrosis is termed "replacement" and is viewed as an adaptive process that preserves the structural integrity of the heart. Cardiac fibrosis also occurs independently of myocyte loss, in which case it is termed "interstitial" fibrosis and is less clearly adaptive. 1 The mechanisms that drive cardiac fibrosis are poorly understood.
Efforts to elucidate mechanisms causing fibrosis in other organs have focused on identifying either increased ECM synthesis (ie, increased expression of genes encoding matrix proteins) 6 or decreased ECM degradation (ie, deficient ECM proteolysis). 7 However, several studies suggest that increased protease activity in the heart may, paradoxically, contribute to fibrosis. For example, matrix metalloproteinase (MMP) activity is increased in failing human hearts. 8 Moreover, mouse hearts overexpressing human MMP-1 have increased collagen accumulation. 9 After experimental myocardial infarction, mice deficient in MMP-9 have less cardiac collagen accumulation than wild-type mice, 10 and administration of MMP inhibitors decreases cardiac collagen accumulation in animal models of cardiomyopathy and myocardial infarction. 11, 12 These data support a role for MMP activity in the pathogenesis of cardiac fibrosis.
The serine protease urokinase plasminogen activator (uPA) and its substrate plasminogen might also play a role in cardiac fibrosis. A role for the uPA/plasminogen system in cardiac fibrosis is suggested by experiments in which mice deficient in uPA or plasminogen were less able to form fibrotic scars after myocardial infarction. 13, 14 Absence of uPA or plasminogen in these mice appears to impair the ability of fibroblasts to migrate into infarcted tissue and synthesize collagen. According to this model, excess uPA activity or, alternatively, deficiency of a uPA inhibitor might each be sufficient to cause cardiac fibrosis.
We recently generated transgenic mice with macrophagespecific overexpression of uPA (SR-uPA ϩ/0 mice) and showed that when bred into the apolipoprotein E (apoE) null background, the SR-uPA transgene accelerated atherosclerosis. 15 Here we report use of SR-uPA ϩ/0 mice and mice deficient in PA inhibitor-1 (PAI-1, the physiologic inhibitor of uPA) to test the hypothesis that elevated uPA activity or lack of a uPA inhibitor can cause cardiac fibrosis.
Materials and Methods

Experimental Animals
Transgenic mice with macrophage-targeted overexpression of uPA (SR-uPA ϩ/0 mice) were described previously. 15 Nontransgenic C57BL/6 Apoe Ϫ/Ϫ mice (used as bone marrow transplant recipients), C57BL/6 mice deficient in PAI-1 (Serpine1 Ϫ/Ϫ ), and C57BL/6 Serpine1 ϩ/ϩ controls were purchased (The Jackson Laboratory). Some mice were fed a Western-type diet containing 21% fat and 0.15% cholesterol (TD88137; Harlan-Tekland) beginning at 5 weeks of age. Bone marrow recipients were fed this diet beginning after transplantation (8 weeks of age). Serpine1 Ϫ/Ϫ mice and their controls were not fed the Western-type diet. All mice except for the bone marrow donors were female.
Lipid Analysis
Plasma cholesterol was measured with a colorimetric assay (Spectrum cholesterol assay; Abbott Laboratories).
Immunostaining and Histochemistry
In initial experiments, mice were perfused via cardiac puncture with 0.9% saline followed by buffered formalin. Tissues were stored in formalin and embedded in paraffin. In later experiments, mice were exsanguinated, hearts were excised, placed in PBS with 5% dextrose, 25 mmol/L KCl, then fixed and processed into paraffin. Serial sections were cut at 4 levels: the aortic root and the base, midventricle, and apex of the heart. Sections of lung, liver, and kidney were also processed into paraffin. Macrophages and leukocytes were detected with rat anti-mouse monoclonal antibodies: anti-Mac-3 clone M3/84 and anti-mouse CD45 clone 30-F11, respectively (Pharmingen). Bound antibody was detected with peroxidaseconjugated goat anti-rat IgG (Kirkegaard & Perry Laboratories). Control slides were incubated with isotype-matched primary antibodies (Pharmingen). Other sections were stained with hematoxylin and eosin (H&E), Masson trichrome, or picrosirius red.
Quantification of Leukocytes, Macrophages, and Collagen in Tissue Sections
Leukocyte (CD45) and macrophage (Mac-3) infiltration were quantified by counting stained cells in 10 high-power (ϫ400) microscopic fields in each of 3 step sections per heart (30 fields per heart). In some mice, Mac-3-positive and CD45-positive cells were also counted in 10 high-power fields of a section of lung. Sections of heart, kidney, liver, lung, and spleen were also stained with H&E and Masson trichrome to assess qualitatively whether fibrosis was present. In mice in which cardiac fibrosis was evident (and in their matched controls), collagen accumulation was quantified by picrosirius red staining of a section from the midventricle and computerassisted planimetry (Image Pro 3.0 software; Media Cybernetics).
Measurement of Plasminogen Activator Activity
Mice were exsanguinated by saline perfusion. Hearts, lungs, and kidneys were sliced into 1-mm-thick sections, which were incubated overnight at 37°C in M199 medium. Plasminogen activator (PA) activity was detected by incubating aliquots of explant culture media with glu-plasminogen (0.4 mol/L; American Diagnostica) and the plasmin substrate S-2251 (0.9 mmol/L; Chromogenix) and measuring optical density at 405 nm.
Bone Marrow Transplantation
Eight-week-old female nontransgenic Apoe Ϫ/Ϫ mice were lethally irradiated. Eight-week-old, male Apoe Ϫ/Ϫ mice (either SR-uPA ϩ/0 or nontransgenic) were used as donors of 6ϫ10 6 bone marrow cells per recipient. 16 
Statistical Analysis
Data are presented as meanϮSD for normally distributed data or median (25% to 75% range) for data not normally distributed. Group means were compared with the t test, and medians were compared with the Mann-Whitney rank-sum test.
Additional details of the materials and methods used can be found in the online data supplement available at http://circres.ahajournals.org.
Results
Macrophage and Collagen Accumulation in Hearts of SR-uPA
In a previous study, we reported that macrophage-targeted overexpression of uPA in Apoe Ϫ/Ϫ mice (SR-uPA ϩ/0 Apoe Ϫ/Ϫ mice) caused accelerated aortic atherosclerosis, severe proximal coronary artery stenoses, complete coronary occlusions, myocardial infarcts, and early mortality. 15 As expected, on the basis of our previous examination of H&E-stained sections, hearts of 15-week-old SR-uPA ϩ/0 Apoe Ϫ/Ϫ mice had significantly more collagenous scar formation than hearts of nontransgenic Apoe Ϫ/Ϫ mice (10% [8.8% to 13%] versus 0.015% [0.0% to 0.075%] picrosirius red positive area; PϽ0.001; Figure 1 ). SR-uPA ϩ/0 Apoe Ϫ/Ϫ hearts were also larger (Table) The presence of collagenous scars and inflammation in hearts but not in other organs of mice with occlusive coronary disease was not surprising. However, the patterns of inflammation and collagen accumulation in SR-uPA
hearts differed from what one would expect if these histologic findings were attributable only to ischemic necrosis. Specifically, inflammation and collagen accumulation were not always circumscribed (ie, confined to territories supplied by individual epicardial coronary arteries). Rather, they were often diffuse and patchy ( Figure 1D , 1F, and 1H). We hypothesized that uPA-secreting macrophages, migrating through the heart toward areas of infarction or attracted to the heart independently of ischemic necrosis, might cause cardiac fibrosis.
Macrophage Accumulation in Hearts of SR-uPA
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Apoe
؊/؊ Mice Aged 3 to 5 Weeks
To begin to test the hypothesis that SR-uPA ϩ/0 macrophages accumulate in the heart and cause cardiac fibrosis indepen-dently of ischemic heart disease, we examined hearts of SR-uPA ϩ/0 and nontransgenic Apoe Ϫ/Ϫ mice aged 3 and 5 weeks (ie, before development of significant atherosclerosis). Sections of hearts of 3-and 5-week-old Apoe Ϫ/Ϫ mice (either SR-uPA ϩ/0 or nontransgenic) did not show abnormal collagen accumulation (H&E and Masson's trichrome stains; data not shown). The 3-week-old hearts were not enlarged (Table) and contained few leukocytes, with no increase in SR-uPA Figure 2B ). Thus, leukocytes, including macrophages, accumulate in SR-uPA ϩ/0 hearts before Heart weight, mg (n) 46Ϯ8 (7) 45Ϯ9 (9) 86Ϯ24 (8) 74Ϯ12 (9) 121Ϯ16 (7) *137Ϯ11 (8) 123Ϯ8 (6) **140Ϯ19 (9) 136Ϯ7 (6) 144Ϯ21 (10) Heart/body weight ratio (n) 6.8Ϯ0.9 (7) 6.6Ϯ0.7 (9) 5.7Ϯ0.9 (9) 5.4Ϯ1.0 (9) 5.3Ϯ0.7 (7) *6.2Ϯ0.7 (8) 5.0Ϯ0.5 (6) *6.1Ϯ1.1 (9) 4.6Ϯ0.5 (6) 5.0Ϯ0.7 (10) Values represent meanϮSD. n indicates the number of mice in each group. *PϽ0.05; **Pϭ0.058 vs non-tg.
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the onset of occlusive coronary artery disease or cardiac fibrosis.
uPA Accumulation in SR-uPA
Because only the hearts of SR-uPA ϩ/0 mice appeared abnormal, we hypothesized that uPA protein, secreted by transgenic macrophages, might accumulate selectively in SRuPA ϩ/0 hearts, reaching levels that are higher than in other organs, and initiating tissue damage. To test this hypothesis, we explanted hearts, lungs, and kidneys from 5-week-old mice (ie, before onset of fibrosis) and measured uPA released from these organs ( Figure 2C ). We chose lungs because they are relatively rich in macrophages and kidneys because they are the predominant site of uPA production in mice. 15, 17 As expected, in nontransgenic mice, uPA levels were higher in kidney explant cultures than in lung or heart cultures. Cultures of SR-uPA ϩ/0 organs contained higher levels of uPA than corresponding cultures of nontransgenic organs. However, SR-uPA ϩ/0 heart cultures contained far less uPA than SR-uPA ϩ/0 kidney or lung cultures. Moreover, SR-uPA
heart cultures contained approximately the same amount of uPA as nontransgenic kidney cultures. Thus, nontransgenic kidneys and SR-uPA ϩ/0 kidneys and lungs contain as much or more uPA as SR-uPA ϩ/0 hearts, yet SR-uPA ϩ/0 hearts become inflamed and fibrotic, whereas kidneys and lungs remain normal in appearance. Therefore, the pathology observed in SR-uPA ϩ/0 hearts cannot be attributed solely to selective accumulation of high levels of uPA in hearts versus other organs.
Transplantation of SR-uPA ؉/0 Bone Marrow to Nontransgenic Mice
Because cardiac macrophage accumulation in SR-uPA ϩ/0 mice preceded cardiac fibrosis, it seemed likely that SRuPA ϩ/0 macrophages caused cardiac fibrosis. However, we could not exclude the possibility that low-level SR-uPA transgene expression in nonhematogenous cells of the heart caused subtle cardiac damage, provoking macrophage accumulation as a secondary event. We therefore tested whether presence of the SR-uPA ϩ/0 transgene in hematogenous cells is sufficient to cause macrophage and collagen accumulation in the heart. Bone marrow was transplanted from male Apoe figure] ). Thus, SR-uPA ϩ/0 macrophages accumulate specifically in the heart and cause cardiac fibrosis independent of the presence of the SR-uPA ϩ/0 transgene in nonhematogenous cells.
Macrophage and Collagen Accumulation in Hearts of SR-uPA
Our experiments suggested that elevated macrophage uPA expression is sufficient to cause cardiac macrophage accumulation and fibrosis. However, these experiments were all performed in Apoe Ϫ/Ϫ mice, leaving the possibility that absence of apoE, severe hyperlipidemia, atherosclerosis, or associated myocardial damage might be required for the effects of elevated macrophage uPA expression to be manifest. To exclude these possibilities, we bred the SR-uPA ϩ/0 transgene into the Apoe ϩ/ϩ background and examined hearts of SR-uPA ϩ/0 Apoe ϩ/ϩ mice. To avoid introducing diet as an uncontrolled variable, Apoe ϩ/ϩ mice (SR-uPA ϩ/0 and nontransgenic littermate controls) were fed the Western-type diet beginning at 5 weeks of age. The SR-uPA transgene does not cause early mortality in Apoe ϩ/ϩ mice. 15 Mice were killed 10 weeks later. As expected, plasma cholesterol in Apoe ϩ/ϩ mice fed the atherogenic diet was only minimally elevated and did not differ between SR-uPA ϩ/0 mice (132Ϯ18 mg/dL; nϭ7) and nontransgenic controls (155Ϯ36 mg/dL; nϭ7; Pϭ0.13). Examination of aortic roots of several Apoe ϩ/ϩ mice (4 SR-uPA ϩ/0 and 2 nontransgenic) revealed no atherosclerosis. However, SR-uPA ϩ/0 Apoe ϩ/ϩ mice had more massive hearts 
PAI-1-Deficient Mice Develop Cardiac Fibrosis
Cardiac fibrosis in SR-uPA ϩ/0 (transgenic) mice and recipients of SR-uPA ϩ/0 bone marrow appeared to be caused by elevated cardiac uPA activity attributable to the presence of SR-uPA ϩ/0 macrophages. Alternatively, fibrosis could be attributable to enhanced cardiac macrophage accumulation in SR-uPA ϩ/0 mice, with uPA-independent macrophage-related cardiotoxicity. To begin to discriminate these possibilities, we tested whether Serpine1 Ϫ/Ϫ mice (deficient in PAI-1, the major physiologic inhibitor of uPA) would develop cardiac fibrosis. To maximize our ability to detect fibrosis, we examined hearts of older C57BL/ 
Discussion
We investigated whether mice with macrophage-targeted overexpression of uPA (SR-uPA ϩ/0 mice) or deficiency of PAI-1 develop cardiac fibrosis independently of atherosclerosis. Our major findings were as follows: (1) into nonatherosclerotic Apoe ϩ/ϩ mice; and (5) Mice deficient in PAI-1 develop cardiac macrophage accumulation and fibrosis. These data suggest that macrophage-expressed uPA plays a critical role in regulating macrophage migration to the heart and in development of cardiac fibrosis.
The molecular and cellular mechanisms that cause cardiac fibrosis are poorly understood. Increased ECM production, a prerequisite for the development of cardiac fibrosis, occurs when cardiac fibroblasts are "activated" to a "myofibroblast" phenotype in settings such as infarction, hypertension, and cardiomyopathy. 1, 18 The stimuli that promote myofibroblast activation in vivo are thought to include angiotensin II, aldosterone, transforming growth factor type ␤ 1 (TGF-␤ 1 ), endothelin, catecholamines, stretch, hypoxia, and diabetes. 5,19 -22 Myofibroblasts activated by these stimuli increase production of ECM components such as collagen, fibronectin, and laminin. 5, 18, 20 When cardiac ECM synthesis outpaces degradation by cardiac MMPs, cardiac fibrosis develops. 21 Paradoxically, despite the requirement that ECM synthesis outpace MMP-mediated ECM degradation for cardiac fibrosis to develop, extensive data implicate MMP-mediated ECM degradation in initiation of cardiac fibrosis. These data include early upregulation of MMPs during the transition from cardiac hypertrophy to dilation 23 and the finding that MMPs facilitate myofibroblast migration and upregulate the activity of potentially fibrogenic cytokines such as TNF-␣ and TGF-␤ 1 . 24 To test more directly whether increased MMP activity can cause cardiac fibrosis, Kim et al overexpressed human MMP-1 in mouse hearts and found increased cardiac fibrosis at 6 months of age. 9 This observation led to the hypothesis that collagen degradation products, generated by active MMP-1, stimulated collagen synthesis by cardiac fibroblasts. Development of cardiac fibrosis in mice with cardiac MMP-1 overexpression supports a cause-and-effect relationship between elevated cardiac protease expression and fibrosis. However, the applicability of this animal model to human cardiac fibrosis (which is a progressive condition) is limited by the fact that the predominant phenotype of the MMP-1-overexpressing mice is cardiac hypertrophy rather than fibrosis. In addition, by 12 months of age, MMP-1-overexpressing mice have less cardiac fibrosis than nontransgenic controls. Therefore, an animal model of proteaseinduced, progressive cardiac fibrosis has not yet been reported.
Here we report that overexpression of uPA, a protease outside the MMP family, causes cardiac fibrosis. Cardiac fibrosis in SR-uPA ϩ/0 mice is evident at 10 weeks of age and persists for Ն1 year (data not shown). Others have suggested that uPA might initiate cardiac fibrosis through activation of MMPs. 22 Nevertheless, our report is the first to show that overexpression of uPA is sufficient to cause cardiac fibrosis. The absence of cardiac fibrosis in mice that overexpress uPA in hepatocytes 25 suggests that macrophage-expressed uPA rather than elevated uPA per se is critical in generating the phenotypes reported here.
There are 2 hypothetical pathways through which uPA could cause cardiac fibrosis: (1) primary activation of cardiac fibroblasts (the "fibroblast activation" hypothesis); and (2) primary cardiomyocyte toxicity with secondary, reactive fibrosis (the "cardiotoxic" hypothesis). The fibroblast activation hypothesis proposes that uPA activates cardiac fibroblasts indirectly through plasmin-mediated activation of MMPs 26 or TGF-␤ 1 . 27 Alternatively, uPA could increase cardiac ECM proteolysis, releasing fibrogenic ECM-derived peptides. 28 The cardiotoxic hypothesis proposes that uPA overexpression is directly toxic to cardiomyocytes. For example, accelerated plasminogen activation and fibrinolysis could cause myocardial hemorrhage and infarction. To examine this possibility, we counted erythrocytes in sections taken from hearts of 5-week-old SR-uPA ϩ/0 Apoe Ϫ/Ϫ and nontransgenic Apoe Ϫ/Ϫ mice (nϭ8 from each group). There was no difference between the groups (1.9ϫ10 3 erythrocytes/mm 2 in both groups; Pϭ0.8). Moreover, we never observed spontaneous hemorrhage in SR-uPA ϩ/0 mice, suggesting that they have normal hemostasis. In contrast, mice lacking fibrinogen have abnormal hemostasis but do not develop cardiac fibrosis. 29 Therefore, uncontrolled fibrinolysis does not appear to be the cause of cardiac fibrosis in SR-uPA ϩ/0 mice. Alternatively, uPA could damage cardiomyocytes by plasmindependent MMP activation leading to proteolysis of cellmatrix contacts. Disruption of these contacts could cause cardiomyocyte dysfunction and death. 30, 31 However, we did not find any differences in levels of active MMP-2 or MMP-9 32 in zymograms of heart extracts from 5-week-old SR-uPA ϩ/0 and nontransgenic mice (data not shown). Nevertheless, we cannot exclude that other MMPs are activated in SR-uPA ϩ/0 mice or that MMP-2, MMP-9, or other proteases might be activated at other time points. Further experimentation is required to elucidate the mechanisms of uPAmediated cardiac fibrosis.
Perhaps the most intriguing aspect of our data is our finding that the heart is uniquely susceptible to macrophage infiltration and fibrosis caused by either overexpression of uPA or absence of PAI-1. uPA-expressing macrophages that are either autologous or were transplanted from a congenic donor accumulate specifically in the heart. This observation is reminiscent of the requirement for uPA, plasminogen, and infiltrating leukocytes in postinfarction myocardial scarring 13 and confirms a critical role for uPA in myocardial collagen accumulation. The SR-uPA ϩ/0 mouse will be useful for investigations that identify mediators of macrophage migration to the heart and pinpoint mechanisms of myocardial collagen synthesis. Insights into these mechanisms will be useful in developing therapies that prevent myocarditis, enhance infarct healing, and prevent cardiac failure and fibrosis.
Finally, our data suggest a new physiologic role for PAI-1: cardioprotection. Because PAI-1 null mice have relatively unopposed uPA activity, spontaneous cardiac fibrosis in these mice is consistent with our finding of cardiac fibrosis in SR-uPA ϩ/0 mice and with the report of impaired collagenous scar formation in infarcted hearts of uPA null mice. 13 However, these data contrast with results obtained in animal models of lung and kidney fibrosis, in which PAI-1 overexpression causes fibrosis, whereas PAI-1 deficiency or uPA overexpression protects from fibrosis. 7, 33, 34 In addition, a recent report of decreased perivascular fibrosis in infarcted hearts of Serpine1 Ϫ/Ϫ mice 35 appears to conflict with our finding of increased fibrosis in hearts of aging Serpine1 Ϫ/Ϫ mice.
We propose a 2-part hypothesis to reconcile our finding of increased cardiac fibrosis in Serpine1 Ϫ/Ϫ mice with reports of decreased fibrosis in Serpine1 Ϫ/Ϫ mice. First, absence of PAI-1 may have opposite consequences in uninjured versus injured tissues. In all reports of decreased fibrosis in Serpine1 Ϫ/Ϫ mice, fibrosis occurred after an injury. However, in the present study, fibrosis occurs without an injury: Serpine1 Ϫ/Ϫ mice simply develop cardiac fibrosis as they age. It is likely that animal models of tissue injury reveal a role for PAI-1 in wound healing. The primary role of PAI-1 in wound healing may be to preserve fibrous scar tissue. In contrast, in the uninjured heart, the primary role of PAI-1 may be inhibition of uPA and prevention of uPA-induced cardiac fibrosis. The concept of a molecule having opposite, contextspecific effects is well established. Indeed, PAI-1 either inhibits or promotes angiogenesis and cell migration, depending on the biological context. 36 The second part of a hypothesis that would explain the apparently paradoxical increase in cardiac fibrosis in Serpine1 Ϫ/Ϫ mice is that the heart is particularly susceptible to damage by dysregulated proteolysis. Unlike other organs, the heart is in constant motion with alternating contraction and relaxation and is also subject to repetitive hemodynamic stresses. Resisting these stresses and performing the work of systole and diastole requires coordination of cardiomyocyte function, which is normally achieved by proteins that link cardiomyocytes and their cytoskeletons to the surrounding ECM and to each other. These proteins include the dystrophin/sarcoglycan complex and matrix proteins such as laminin, to which this complex attaches. 37 Proteolysis of this complex causes cardiomyopathy. 38 Fibrosis might develop in hearts but not in other organs of Serpine1 Ϫ/Ϫ mice because of a unique dependence of the heart on extracellular proteinprotein interactions and an intact ECM. It will be interesting to investigate whether inappropriate cardiac fibrosis in humans is accompanied by genetic 39 or environmental 40 factors that cause elevated protease activity or decrease the activity of protease inhibitors.
